Looking at the results released by Novo Nordisk this morning and listening to the earnings call the transformation initiated by the company continues to move ahead. Like their main competitor Lilly, Novo is also adjusting to the impact of COVID. The good news is that things aren’t as bad as initially anticipated. The fact is until COVID is gone everyone is adjusting to this new normal and the new normal basically seems to be slower growth.
The results also show how important obesity products, GLP-1’s repositioned from diabetes to obesity treatments, have become to the company.
This content is restricted to subscribers. Please subscribe. Already have an account? Please login.
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.